News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Drug Development
Takeda Pharmaceuticals North America, Inc.'s Actos Has Same Heart Risks as GlaxoSmithKline’s Avandia, Researchers Find
August 25, 2010
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
Bloomberg -- Takeda Pharmaceutical Co.’s diabetes drug Actos causes as many heart problems as Avandia, the GlaxoSmithKline Plc pill that had a decline in sales after being linked to higher heart-disease rates, a study found.
Twitter
LinkedIn
Facebook
Email
Print
Clinical research
Postmarket research
Europe
GlaxoSmithKline
Takeda
MORE ON THIS TOPIC
Weight Loss
Despite Novo’s Robust Oral Wegovy Launch, Access Remains a Challenge for Obesity Drugs
March 25, 2026
·
3 min read
·
Heather McKenzie
Cancer
Karyopharm Slides as Mixed Myelofibrosis Results Cloud Regulatory Road
March 25, 2026
·
2 min read
·
Tristan Manalac
Podcast
Gilead’s Ouro Buy, J&J/Protagonist’s Approval, Aurinia’s Revamp, ACIP Confusion, More
March 25, 2026
·
1 min read
·
Heather McKenzie
Obesity
Aardvark Pauses 2 Obesity Trials, Reveals New Details on Cardiac Concerns
March 24, 2026
·
2 min read
·
Tristan Manalac